How has Novartis (NOVARTIND) been performing? We dig into revenue, profitability, valuation, and ownership trends.
Novartis Revenue Trend
Compared to ₹335 Cr in FY2024, Novartis's FY2025 revenue of ₹356 Cr marks a 6.3% improvement.
Over the past 10 years, revenue has declined sharply at 8.6% per year, from ₹873 Cr to ₹356 Cr. This is a significant erosion of the top line.
Novartis is a smaller pharmaceuticals company by revenue, with a top line of ₹356 Cr.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | ₹356 Cr | +6.3% |
| FY2024 | ₹335 Cr | -11.5% |
| FY2023 | ₹379 Cr | -5.3% |
| FY2022 | ₹400 Cr | -3.5% |
| FY2021 | ₹414 Cr | — |
View Novartis's full 10-year revenue trend with CAGR analysis →
Novartis Profitability
Bottom-line growth was evident, with Novartis posting ₹101 Cr in net profit for FY2025 — up 18.4% from ₹85.2 Cr.
A stronger net margin of 28.3% in FY2025 (from 25.4%) points to better profitability per rupee of revenue.
Per-share earnings moved to ₹40.87 in FY2025 from ₹34.50 in FY2024.
Is Novartis Undervalued
Novartis shares are currently trading at ₹1,626.25.
Craytheon calculates intrinsic value using the P/E Ratio, DCF, and EPS Growth models. All three appear in the Valuation Models cards below.
Valuation Models
Novartis Shareholding Pattern
At 70.7%, the promoter stake has been flat for the past 4 quarters.
Foreign institutional investors (FIIs) held 0.2% as of March 2026, down from 0.2% a year ago.
The DII stake is flat at 0.5% as of March 2026, unchanged from the year-ago period.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Mar 2026 | 70.7% | 0.2% | 0.5% | 28.6% |
| Dec 2025 | 70.7% | 0.2% | 0.6% | 28.5% |
| Sep 2025 | 70.7% | 0.2% | 0.5% | 28.6% |
| Jun 2025 | 70.7% | 0.2% | 0.5% | 28.6% |
Track quarterly shareholding changes for Novartis →
Novartis Balance Sheet
Proportional view as of 3 Aug 2026. Hover blocks for details.
Assets
Liabilities & Equity
FY2025 total assets: ₹9.48B (up 2.5% YoY from ₹9.25B).
Top categories: Cash & ST Investments (68.4%), Other Assets (23.0%), Inventories (4.3%).
Of the ₹9.48B in liabilities and equity, 82.8% is shareholder equity, 0.5% is interest-bearing debt, and 16.6% is operating liabilities. Over the year, debt is down 27.4% and equity is up 5.4%.
Balance sheet composition — FY 2025
| Category | Value |
|---|---|
| Cash & ST Investments | 6.48B |
| Receivables | 401.40M |
| Inventories | 411.10M |
| Property, Plant & Equipment | 9.70M |
| Other Assets | 2.18B |
| Category | Value |
|---|---|
| Equity | 7.85B |
| Short-term Debt | 18.50M |
| Long-term Debt | 32.10M |
| Trade Payables | 514.70M |
| Other Liabilities | 1.06B |
Novartis at a Glance
To sum up Novartis's financial position: the data paints a clear picture for investors evaluating this pharmaceuticals stock.
Revenue of ₹356 Cr in FY2025, up 6.3% year-over-year.
Long-term revenue has been contracting at 8.6% annually over 10 years.
The company is profitable, with a net margin of 28.3% and net income of ₹101 Cr.
Unlock Full Analysis
See the full picture — Craytheon tracks 10 years of financial data with interactive charts, growth trends, and three valuation models for Novartis.